What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Portfolio Pulse from Vandana Singh
On Wednesday, Madrigal Pharmaceuticals (MDGL) and Sagimet Biosciences (SGMT) stocks are trading lower following Eli Lilly's (LLY) presentation of positive Phase 2 trial results for tirzepatide in treating MASH at the EASL International Liver Congress 2024. Other companies working on MASH candidates include 89bio (ETNB), Akero Therapeutics (AKRO), and Viking Therapeutics (VKTX).
June 05, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Madrigal Pharmaceuticals' stock is down 5.14% following Eli Lilly's positive Phase 2 trial results for tirzepatide in treating MASH, which may impact the competitive landscape for Madrigal's fatty liver disease treatments.
Eli Lilly's positive trial results for tirzepatide could pose a competitive threat to Madrigal's own treatments for fatty liver disease, leading to a decline in MDGL's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Sagimet Biosciences' stock is down 7.22% as Eli Lilly's positive Phase 2 trial results for tirzepatide in MASH treatment may overshadow Sagimet's own efforts in the same field.
The positive results from Eli Lilly's tirzepatide trial could overshadow Sagimet's efforts in MASH treatment, leading to a decline in SGMT's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Akero Therapeutics, also working on MASH candidates, might experience a positive impact as Eli Lilly's tirzepatide results underscore the market potential for MASH treatments.
The positive trial results for tirzepatide by Eli Lilly could highlight the potential in the MASH treatment market, benefiting Akero Therapeutics.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
89bio, working on MASH candidates, may see increased investor interest following Eli Lilly's positive tirzepatide trial results, highlighting the potential in the MASH treatment market.
Eli Lilly's positive results for tirzepatide in MASH treatment could draw attention to other companies in the same field, potentially benefiting 89bio.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Eli Lilly's presentation of positive Phase 2 trial results for tirzepatide in MASH treatment at the EASL International Liver Congress 2024 is likely to boost investor confidence and positively impact the stock.
The positive trial results for tirzepatide in treating MASH are likely to boost investor confidence in Eli Lilly's stock, as it demonstrates the potential efficacy of their treatment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 70
POSITIVE IMPACT
Viking Therapeutics, involved in MASH treatment development, may see a positive impact as Eli Lilly's tirzepatide results highlight the potential in the MASH treatment market.
Eli Lilly's positive tirzepatide trial results could draw attention to the MASH treatment market, potentially benefiting Viking Therapeutics.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 50